Evaluation of the oral administration of α-l-guluronic acid on COX-1 and COX-2 gene expression profile in ankylosing spondylitis patients.
Administration, Oral
Adolescent
Adult
Cyclooxygenase 1
/ biosynthesis
Cyclooxygenase 2
/ biosynthesis
Cyclooxygenase 2 Inhibitors
/ administration & dosage
Female
Hexuronic Acids
/ administration & dosage
Humans
Leukocytes, Mononuclear
/ drug effects
Male
Middle Aged
Spondylitis, Ankylosing
/ drug therapy
Transcriptome
/ drug effects
Young Adult
COX-1
COX-2
G2013
NSAIDs
ankylosing spondylitis
guluronic acid
Journal
Drug development research
ISSN: 1098-2299
Titre abrégé: Drug Dev Res
Pays: United States
ID NLM: 8204468
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
revised:
09
09
2020
received:
02
12
2019
accepted:
22
10
2020
pubmed:
4
11
2020
medline:
9
3
2022
entrez:
3
11
2020
Statut:
ppublish
Résumé
Ankylosing spondylitis (AS) is a chronic autoimmune arthritis disease with a genetic background, affecting the skeletal axis, sacroiliac, and peripheral joints. Nonsteroidal anti-inflammatory drugs (NSAIDs) are the first-line treatment for AS to alleviate the inflammation and pain. Despite the beneficial effect, their use is accompanied by a wide variety of possible side effects in the gastrointestinal and kidneys. The α-l-guluronic acid (G2013) is a new nonsteroidal anti-inflammatory patented (PCT/EP2017/067920) drug, which has shown its anti-inflammatory properties in the previous investigations. The present study revealed the oral administration effect of G2013 on COX-1 and COX-2 gene expression in AS patients. The blood samples of twelve 18-45 years old patients suffering AS and BASDAI >4, and BASFI >4, before and after 12 weeks of treatment with G2013 and 12 blood samples of healthy volunteers were collected and the effect of G2013 on the gene expression of COX-1 and COX-2 enzymes were assessed by Real-Time PCR. The results indicate that G2013 is able to reduce the gene expression level of COX-1 and COX-2 enzymes in treated AS patients compared to healthy control. Statistically significant differences were not observed between the treatment and the healthy control groups. According to the findings, G2013 might be categorized and introduced as a novel NSAID for the treatment of AS.
Substances chimiques
Cyclooxygenase 2 Inhibitors
0
Hexuronic Acids
0
guluronic acid
15769-56-9
Cyclooxygenase 1
EC 1.14.99.1
Cyclooxygenase 2
EC 1.14.99.1
PTGS1 protein, human
EC 1.14.99.1
Types de publication
Clinical Trial, Phase I
Clinical Trial, Phase II
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
296-301Informations de copyright
© 2020 Wiley Periodicals LLC.
Références
Afraei, S., Azizi, G., Zargar, S. J., Sedaghat, R., & Mirshafiey, A. (2015). New therapeutic approach by G2013 in experimental model of multiple sclerosis. Acta Neurologica Belgica, 115(3), 259-266. https://doi.org/10.1007/s13760-014-0392-x.
Alexanian, A., Miller, B., Chesnik, M., Mirza, S., & Sorokin, A. (2014). Post-translational regulation of COX2 activity by FYN in prostate cancer cells. Oncotarget, 5(12), 4232-4243. https://doi.org/10.18632/oncotarget.1983.
Appleby, S. B., Ristimaki, A., Neilson, K., Narko, K., & Hla, T. (1994). Structure of the human cyclo-oxygenase-2 gene. Biochemical Journal, 302 (Pt 3, 723-727.
Arjomand Fard, N., Tabrizian, N., Mirzaei, R., Hadjati, J., Tofighi Zavareh, F., Salehi Nodeh, A. R., & Mirshafiey, A. (2017). Efficacy and safety of G2013 as a novel immunosuppressive agent on differentiation, maturation and function of human dendritic cells. Iranian Journal of Public Health, 46(2), 216-221.
Braun, J., Bollow, M., Remlinger, G., Eggens, U., Rudwaleit, M., Distler, A., & Sieper, J. (1998). Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. Arthritis and Rheumatism, 41(1), 58-67. https://doi.org/10.1002/1529-0131(199801)41:1<58::AID-ART8>3.0.CO;2-G.
Chandrasekharan, N. V., Dai, H., Roos, K. L., Evanson, N. K., Tomsik, J., Elton, T. S., & Simmons, D. L. (2002). COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: Cloning, structure, and expression. Proceedings of the National Academy of Sciences of the United States of America, 99(21), 13926-13931. https://doi.org/10.1073/pnas.162468699.
Chen, M., Boilard, E., Nigrovic, P. A., Clark, P., Xu, D., Fitzgerald, G. A., … Lee, D. M. (2008). Predominance of cyclooxygenase 1 over cyclooxygenase 2 in the generation of proinflammatory prostaglandins in autoantibody-driven K/BxN serum-transfer arthritis. Arthritis and Rheumatism, 58(5), 1354-1365. https://doi.org/10.1002/art.23453.
Coxib and traditional NSAID Trialists' (CNT) Collaboration, Bhala, N., Emberson, J., Merhi, A., Abramson, S., … Baigent, C. (2013). Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: Meta-analyses of individual participant data from randomised trials. Lancet, 382(9894), 769-779. https://doi.org/10.1016/S0140-6736(13)60900-9.
Farhang, H., Sharifi, L., Dallal, M. M. S., Moshiri, M., Norouzbabaie, Z., Bokaie, S., … Mirshafiey, A. (2018). The immunomodulatory role of G2013 (a-L-Guluronic acid) on the expression of TLR2 and TLR4 in HT29 cell line. Current Drug Discovery Technologies, 16, 91-95. https://doi.org/10.2174/1570163815666180226093711.
Hajivalili, M., Pourgholi, F., Majidi, J., Aghebati-Maleki, L., Movassaghpour, A. A., Samadi Kafil, H., … Yousefi, M. (2016). G2013 modulates TLR4 signaling pathway in IRAK-1 and TARF-6 dependent and miR-146a independent manner. Cellular and Molecular Biology (Noisy-le-Grand, France), 62(4), 1-5.
Hawkey, C. J. (1999). COX-2 inhibitors. Lancet, 353(9149), 307-314.
Jafarnezhad-Ansariha, F., Yekaninejad, M. S., Jamshidi, A. R., Mansouri, R., Vojdanian, M., Mahmoudi, M., … Mirshafiey, A. (2017). The effects of beta-D-mannuronic acid (M2000), as a novel NSAID, on COX1 and COX2 activities and gene expression in ankylosing spondylitis patients and the murine monocyte/macrophage, J774 cell line. Inflammopharmacology, 26, 375-384. https://doi.org/10.1007/s10787-017-0386-4.
Khadem Azarian, S., Akhlaghi, M., Mahmoudi, M., Mostafaei, S., Jamshidi, A. R., Nazeri, S., & Mirshafiey, A. (2019). A randomized clinical trial for the assessment of the efficacy and safety of guluronic acid (G2013) in patients with rheumatoid arthritis. Immunopharmacology and Immunotoxicology, 41, 1-7. https://doi.org/10.1080/08923973.2018.1555844.
Kroon, F. P., van der Burg, L. R., Ramiro, S., Landewe, R. B., Buchbinder, R., Falzon, L., & van der Heijde, D. (2015). Non-steroidal anti-inflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis and non-radiographic axial spondyloarthritis). Cochrane Database of Systematic Reviews, 7, CD010952. https://doi.org/10.1002/14651858.CD010952.pub2.
Mirshafiey, A., Hosseini, S., Afraei, S., Rastkari, N., Zavareh, F. T., & Azizi, G. (2016). Anti-aging property of G2013 molecule as a novel immunosuppressive agent on enzymatic and non-enzymatic oxidative stress determinants in rat model. Current Drug Discovery Technologies, 13(1), 25-33.
Mirshafiey, A., Mortazavi-Jahromi, S. S., Taeb, M., Cuzzocrea, S., & Esposito, E. (2018). Evaluation of the effect of alpha-L-Guluronic acid (G2013) on COX-1, COX-2 activity and gene expression for introducing this drug as a novel NSAID with immunomodulatory property. Recent Patents on Inflammation & Allergy Drug Discovery, 12(2), 162-168. https://doi.org/10.2174/1872213X12666180607121809.
Mortazavi-Jahromi, S. S., Nazeri, S., Jafarnezhad-Ansariha, F., Oraei, M., & Mirshafiey, A. (2019). Assessment of immunological profile in ankylosing spondylitis patients following a clinical trial with guluronic acid (G2013), as a new NSAID with immunomodulatory properties. Immunologic Research, 67, 108-115. https://doi.org/10.1007/s12026-018-9042-3.
Myers, L. K., Kang, A. H., Postlethwaite, A. E., Rosloniec, E. F., Morham, S. G., Shlopov, B. V., Goorha, S., & Ballou, L. R. (2000). The genetic ablation of cyclooxygenase 2 prevents the development of autoimmune arthritis. Arthritis and Rheumatism, 43(12), 2687-2693. https://doi.org/10.1002/1529-0131(200012)43:12<2687::AID-ANR8>3.0.CO;2-9.
Nazeri, S., Khadem Azarian, S., Fattahi, M. J., Sedaghat, R., Tofighi Zavareh, F., Aghazadeh, Z., … Mirshafiey, A. (2017). Preclinical and pharmacotoxicology evaluation of alpha-l-guluronic acid (G2013) as a non-steroidal anti-inflammatory drug with immunomodulatory property. Immunopharmacology and Immunotoxicology, 39(2), 59-65. https://doi.org/10.1080/08923973.2017.1282512.
Ricciotti, E., & FitzGerald, G. A. (2011). Prostaglandins and inflammation. Arteriosclerosis, Thrombosis, and Vascular Biology, 31(5), 986-1000. https://doi.org/10.1161/ATVBAHA.110.207449.
Samoto, H., Shimizu, E., Matsuda-Honjyo, Y., Saito, R., Nakao, S., Yamazaki, M., … Ogata, Y. (2003). Prostaglandin E2 stimulates bone sialoprotein (BSP) expression through cAMP and fibroblast growth factor 2 response elements in the proximal promoter of the rat BSP gene. The Journal of Biological Chemistry, 278(31), 28659-28667. https://doi.org/10.1074/jbc.M300671200.
Schett, G., & Rudwaleit, M. (2010). Can we stop progression of ankylosing spondylitis? Best Practice & Research. Clinical Rheumatology, 24(3), 363-371. https://doi.org/10.1016/j.berh.2010.01.005.
Shaikh, S. A. (2007). Ankylosing spondylitis: Recent breakthroughs in diagnosis and treatment. The Journal of the Canadian Chiropractic Association, 51(4), 249-260.
Sharifi, L., Mohsenzadegan, M., Aghamohammadi, A., Rezaei, N., Tofighi Zavareh, F., Bokaie, S., … Aghazadeh, Z. (2017). Immunomodulatory effect of G2013 (a-L-Guluronic acid) on theTLR2 and TLR4 in human mononuclear cells. Current Drug Discovery Technologies, 15, 123-131. https://doi.org/10.2174/1570163814666170605111331.
Sieper, J., Braun, J., Rudwaleit, M., Boonen, A., & Zink, A. (2002). Ankylosing spondylitis: An overview. Annals of the Rheumatic Diseases, 61 Suppl 3, 8-18.
Song, I. H., Poddubnyy, D. A., Rudwaleit, M., & Sieper, J. (2008). Benefits and risks of ankylosing spondylitis treatment with nonsteroidal antiinflammatory drugs. Arthritis and Rheumatism, 58(4), 929-938. https://doi.org/10.1002/art.23275.
Taeb, M., Mortazavi-Jahromi, S., Jafarzadeh, A., Mirzaei, M. R., & Mirshafiey, A. (2017). An in vitro evaluation of anti-aging effect of guluronic acid (G2013) based on enzymatic oxidative stress gene expression using healthy individuals PBMCs. Biomedicine & Pharmacotherapy, 90, 262-267. https://doi.org/10.1016/j.biopha.2017.03.066.
Wolf, J., & Fasching, P. (2010). Ankylosing spondylitis. Wiener Medizinische Wochenschrift (1946), 160(9-10), 211-214. https://doi.org/10.1007/s10354-010-0793-2.